Biopharma · FDA Approvals · Stock

KURA Kura Oncology

Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor zi…

Assets on file: ziftomenib

Start live analysis of KURA Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for KURA, including recently decided ones.

March 2027

Mar 2027

~ Mar 2027

KURAKura Oncology

ziftomenib: Phase 2 trial NCT07623616 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

December 2027

Dec 2027

Dec 31, 2027

in 426 days

KURAKura Oncology

ziftomenib: Phase 2 trial NCT06930352 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

October 2028

Oct 2028

Oct 16, 2028

in 716 days

KURAKura Oncology

ziftomenib: Phase 1/Phase 2 trial NCT04067336 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

December 2028

Dec 2028

~ Dec 2028

KURAKura Oncology

ziftomenib: Phase 1/Phase 2 trial NCT05848687 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

November 2031

Nov 2031

~ Nov 2031

KURAKura Oncology

ziftomenib: Phase 3 trial NCT07007312 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Recent first-hand events

Every first-hand event for KURA, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Oct 13, 2026

03:20 PM

KURAKura Oncology

ziftomenib · NCT07007312 registry update

countries: {'total_sites': 122, 'us_sites': 43} → {'total_sites': 136, 'us_sites': 44}

Trial registry changeClinicalTrials.gov

Oct 7, 2026

03:21 PM

KURAKura Oncology

ziftomenib · NCT07007312 registry update

countries: {'total_sites': 115, 'us_sites': 42} → {'total_sites': 122, 'us_sites': 43}

Trial registry changeClinicalTrials.gov

Aug 12, 2026

08:10 PM

KURAKura Oncology

Kura Oncology reports 2Q 2026 financials; KOMZIFTI $9.1M revenue

The 8-K exhibit is a quarterly earnings release that discloses commercial uptake metrics for the recently approved menin inhibitor KOMZIFTI and outlines upcoming clinical data presentations in 2H 2026. No new regulatory filing, PDUFA date, or approval decision is announced.

Conference presentationSEC 8-K

Nov 4, 2025

11:35 AM

KURAKura Oncology

Kura Oncology: ziftomenib PDUFA set for Nov 30, 2025 (R/R NPM1-m AML)

The 8-K confirms the FDA has set a November 30, 2025 PDUFA target action date for ziftomenib monotherapy in relapsed/refractory NPM1-m AML. This is the next regulatory milestone for the asset ahead of potential approval.

PDUFA date setSEC 8-K Open record